Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 3
2019 2
2020 1
2021 7
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Drug repurposing: progress, challenges and recommendations.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Pushpakom S, et al. Nat Rev Drug Discov. 2019 Jan;18(1):41-58. doi: 10.1038/nrd.2018.168. Epub 2018 Oct 12. Nat Rev Drug Discov. 2019. PMID: 30310233 Review.
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L. Zhao Y, et al. Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2077-E2084. doi: 10.1073/pnas.1719966115. Epub 2018 Feb 9. Proc Natl Acad Sci U S A. 2018. PMID: 29440379 Free PMC article.
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW; Synodos for NF2 Consortium. Chang LS, et al. PLoS One. 2021 Jul 15;16(7):e0252048. doi: 10.1371/journal.pone.0252048. eCollection 2021. PLoS One. 2021. PMID: 34264955 Free PMC article.
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Fisher MJ, Belzberg AJ, de Blank P, De Raedt T, Elefteriou F, Ferner RE, Giovannini M, Harris GJ, Kalamarides M, Karajannis MA, Kim A, Lázaro C, Le LQ, Li W, Listernick R, Martin S, Morrison H, Pasmant E, Ratner N, Schorry E, Ullrich NJ, Viskochil D, Weiss B, Widemann BC, Zhu Y, Bakker A, Serra E. Fisher MJ, et al. Am J Med Genet A. 2018 May;176(5):1258-1269. doi: 10.1002/ajmg.a.38675. Am J Med Genet A. 2018. PMID: 29681099 Free PMC article.
Targeted Therapies for the Neurofibromatoses.
Sanchez LD, Bui A, Klesse LJ. Sanchez LD, et al. Cancers (Basel). 2021 Nov 30;13(23):6032. doi: 10.3390/cancers13236032. Cancers (Basel). 2021. PMID: 34885143 Free PMC article. Review.
A Review of Drug Therapy in Vestibular Schwannoma.
Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B. Long J, et al. Drug Des Devel Ther. 2021 Jan 8;15:75-85. doi: 10.2147/DDDT.S280069. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33447015 Free PMC article. Review.
18 results